Fluicell

Fluicell Capital Intensity

The Capital Intensity Ratio of Fluicell (FLUI.ST) as of Nov 20, 2026 is 307.81 %. In the previous year, Capital Intensity Ratio was 1,372.14 % — a change of -77.57% (lower).

Capital Intensity

307.81 %

YoY

-77.57%

Last updated:

Capital Intensity Ratio of Fluicell is 2025 307.81 % . Capital Intensity Ratio of Fluicell was 2024 1,372.14 % . It decreases by -77.57% lower compared to the previous year.

The Fluicell Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
2,118.52 SEK
Jan 1, 2019
801.33 SEK
Jan 1, 2020
535.71 SEK
Jan 1, 2021
1,036.93 SEK
Jan 1, 2022
977.11 SEK
Jan 1, 2023
279.81 SEK
Jan 1, 2024
1,372.14 SEK
Jan 1, 2025
307.81 SEK
The Fluicell Capital Intensity history
YEARCapital IntensityYoY
307.81 %-77.57%
1,372.14 %+390.38%
279.81 %-71.36%
977.11 %-5.77%
1,036.93 %+93.56%
535.71 %-33.15%
801.33 %-62.18%
2,118.52 %+93.21%
1,096.48 %+941.16%
105.31 %-12.60%
120.50 %-89.89%
1,191.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Capital Intensity Ratio of Fluicell is 307.81 % in 2025.

Capital Intensity Ratio of Fluicell changed from 1,372.14 % to 307.81 %, representing a -77.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Fluicell since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Fluicell with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Fluicell

All Key Metrics — Fluicell